Aneela Siddabathuni
Research Subjects
Aneela Siddabathuni has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Nirupama Kandula
Department of Microbiology
1 shared publication - Ramoji Kosuru
Versiti Blood Research Institute, P.O. Box 2178, Milwaukee, WI 53201-2178, USA
1 shared publication - Sanjay Singh
Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow 226025, India
1 shared publication - Saurabh Kumar
Versiti Blood Research Institute, Milwaukee, USA
1 shared publication - Venkatakirankumar Mandlem
Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA
1 shared publication
Latest Publications
- Open Access
- 11 October 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7346699
Role of AMPK in Myocardial Ischemia‐Reperfusion Injury‐Induced Cell Death in the Presence and Absence of Diabetes
Recent studies indicate cell death is the hallmark of cardiac pathology in myocardial infarction and diabetes. The AMP‐activated protein kinase (AMPK) signalling pathway is considered a putative salvaging phenomenon, plays a decisive role in almost all cellular, metabolic, and survival functions, and therefore entails precise regulation of its activity. AMPK regulates various programmed cell death depending on the stimuli and context, including autophagy, apoptosis, necroptosis, and ferroptosis. There is substantial evidence suggesting that AMPK is down‐regulated in cardiac tissues of animals and humans with type 2 diabetes or metabolic syndrome compared to non‐diabetic control and that stimulation of AMPK (physiological or pharmacological) can ameliorate diabetes‐associated cardiovascular complications, such as myocardial ischemia‐reperfusion injury. Furthermore, AMPK is an exciting therapeutic target for developing novel drug candidates to treat cell death in diabetes‐associated myocardial ischemia‐reperfusion injury. Therefore, in this review, we summarized how AMPK regulates autophagic, apoptotic, necroptotic, and ferroptosis pathways in the context of myocardial ischemia‐reperfusion injury in the presence and absence of diabetes.
- 11 October 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7346699
Open AccessRole of AMPK in Myocardial Ischemia‐Reperfusion Injury‐Induced Cell Death in the Presence and Absence of Diabetes
Recent studies indicate cell death is the hallmark of cardiac pathology in myocardial infarction and diabetes. The AMP‐activated protein kinase (AMPK) signalling pathway is considered a putative salvaging phenomenon, plays a decisive role in almost all cellular, metabolic, and survival functions, and therefore entails precise regulation of its activity. AMPK regulates various programmed cell death depending on the stimuli and context, including autophagy, apoptosis, necroptosis, and ferroptosis. There is substantial evidence suggesting that AMPK is down‐regulated in cardiac tissues of animals and humans with type 2 diabetes or metabolic syndrome compared to non‐diabetic control and that stimulation of AMPK (physiological or pharmacological) can ameliorate diabetes‐associated cardiovascular complications, such as myocardial ischemia‐reperfusion injury. Furthermore, AMPK is an exciting therapeutic target for developing novel drug candidates to treat cell death in diabetes‐associated myocardial ischemia‐reperfusion injury. Therefore, in this review, we summarized how AMPK regulates autophagic, apoptotic, necroptotic, and ferroptosis pathways in the context of myocardial ischemia‐reperfusion injury in the presence and absence of diabetes.